Charles River Laboratories (CRL) Q2 2025 Earnings
How Did CRL Stock React to Q2 2025 Earnings?
S&P 500 over the same 30 days: +2.54%.
Did CRL Beat Earnings? Q2 2025 Results
Yes. Charles River Laboratories reported Q2 2025 earnings of $3.12 a share on Aug 6, 2025, beating the $2.50 consensus estimate by 24.6%. Revenue was $1.0B against a $985.1M estimate.
Charles River Laboratories delivered a standout second quarter, posting non-GAAP EPS of $3.12 against a consensus estimate of $2.50, a beat of 24.59%, while revenue of $1.03 billion edged 0.6% higher year-over-year and cleared the $985.08 million consensus by 4.78%. The stronger-than-expected results were driven in large part by dramatic margin expansion in the Manufacturing segment, where non-GAAP operating margins surged to 32.8% from 26.6% a year ago on commercial CDMO revenue, while restructuring savings lifted profitability across all three divisions. Adding further lift to investor sentiment, the company announced it had been cleared in a DOJ grand jury investigation into its non-human primate supply chain, removing a legal overhang that had weighed on the stock for years. Management raised full-year 2025 non-GAAP EPS guidance to a range of $9.90 to $10.30 from $9.30 to $9.80, and narrowed its revenue outlook, as <a href="https://247wallst.com/investing/2025/07/31/stock-market-live-july-31-sp-500-voo-rises-on-positive-china-earnings-news/">broader market tailwinds</a> coincided with CEO James Foster signaling that biopharmaceutical client demand is gradually stabilizing.
- Non-GAAP operating margin improvement across all three segments
- Favorable results in DSA segment drove better-than-expected performance
- RMS organic revenue growth of 2.3% driven by large research models and GEMS/Insourcing Solutions
- Manufacturing organic growth of 2.9% driven by Microbial Solutions business
- Manufacturing non-GAAP margin expansion to 32.8% driven by commercial CDMO client revenue and payments
- Cost savings from restructuring initiatives benefited margins across segments
- Lower diluted shares outstanding from stock repurchase program boosted non-GAAP EPS
- Foreign currency translation added 1.2% to reported revenue
“We are continuing to see clear signs that the biopharmaceutical demand is stabilizing, and in this environment, we are making gradual progress to return to organic revenue growth. This progress was demonstrated in our solid second-quarter financial performance, driven principally by favorable results in our DSA segment.”
Charles River Laboratories CEO, on the earnings call
What Was Charles River Laboratories's Outlook in Q2 2025?
Charles River raised its full-year 2025 guidance. Reported revenue growth is now expected to decline 2.5% to 0.5% (previously a decline of 5.5% to 3.5%), with organic revenue expected to decline 3.0% to 1.0% (previously 4.5% to 2.5%). The favorable impact of foreign exchange is approximately 0.5%. GAAP EPS is expected at $4.25 to $4.65 (previously $4.35 to $4.85). Non-GAAP EPS guidance was raised to $9.90 to $10.30 (from $9.30 to $9.80). The improved outlook primarily reflects better-than-expected Q2 results, particularly in the DSA segment, and a more favorable foreign exchange impact. The company noted that biopharmaceutical demand is stabilizing and it is making gradual progress toward returning to organic revenue growth.
CRL YoY Financials
| Metric | Q2 2025 | Q2 2024 | Year over year |
|---|---|---|---|
| Revenue | $1.0B | $1.0B | +0.6% |
| Operating Income | $100.1M | $151.6M | −34.0% |
| Net Income | $52.3M | $90.0M | −41.9% |
CRL Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.